The Company announced it submitted a supplemental New Animal Drug Application (NADA) for NOCITA® (bupivacaine liposome injectable suspension) with the U.S. Food and Drug Administration’s Center for Veterinary Medicine (CVM).
The Company plans on presenting at Jefferies 2018 Global Healthcare Conference on Tuesday, June 5, 2018 at 4:30 p.m. ET in New York City.
The Company will join a fireside chat at Piper Jaffray’s 27th Healthcare Conference in New York City on December 1, 2015 at 12 p.m. ET. Additionally, Aratana will present at the Bank of America Merrill Lynch 2015 Animal Health Summit in Boston on December 16, 2015 at 8 a.m. ET.
The Company announced plans to present at the Stifel 2015 Healthcare Conference on Tuesday, November 17 at 8:45 a.m. ET in New York City at the New York Place Hotel.
Discover how we’re working to raise the standard of care with novel therapeutics in development for osteoarthritis, post-operative pain, inappetence, lymphoma and osteosarcoma.
The Company shared findings at the 2015 American College of Veterinary Surgeon’s (ACVS) Surgery Summit in Nashville, Tennessee October 21-24 from a pilot clinical field study evaluating effectiveness and duration for post-surgical analgesia in dogs that underwent stifle surgery.
The Company announced its third quarter 2015 financial and operational results.
The Company will host a live conference call on Friday, November 6, 2015 at 8:30 a.m. ET to discuss financial results for the third quarter ending September 30, 2015.
The Company will host an investor day in New York on November 12, 2015. The event will focus on the Company’s R&D pipeline, commercialization of products and financial outlook.
The Company today announced a $40 million senior secured credit facility with Pacific Western Bank, as agent and lender, and Oxford Finance LLC, as lender.
The Company provided an overview of advances for dogs in osteoarthritis and post-operative pain management at the 2015 International Veterinary Emergency & Critical Care Symposium (IVECCS) in Washington, D.C. on September 18-22.
The Company provided several product updates, including that it continues to advance its deep pipeline of novel therapeutics.
The Company announced that the Board of Directors has elected Wendy Yarno as Chairman of Aratana’s Board of Directors.
The Company announced today its second quarter 2015 financial results and product updates
The Company announced that its strategic partner VetStem Biopharma, Inc. has shared positive results from a dose confirmation study of AT-016, an adipose-derived allogeneic stem cell product exclusively licensed to Aratana for the treatment of osteoarthritis pain in dogs.
The Company today announced the positive results of a pilot field study of AT-002 in cats.
The Company today provided an update on the development, manufacturing and commercialization of their monoclonal antibodies (MAbs) targeting canine B-cell lymphoma (AT-004) and canine T-cell lymphoma (AT-005).
The Company will host a conference call and live audio webcast on Friday, August 7, 2015, at 8:30 a.m. ET, to discuss its financial results for the second quarter ended June 30, 2015.